For UK pharmaceutical and life sciences leaders
Your clinical data is strong, but peer adoption and pathway integration are lagging
Prescribing decisions in the UK turn on local formularies, clinical guidelines, and peer networks, not clinical data alone. Without influence across all three, even well-evidenced products stall at launch and beyond.
Two minutes. Solva follows up with specific prescribing influence options.
- New, clinically superior drugs remain on formulary lists but see minimal actual prescriptions in primary and secondary care settings
- Sales representatives report consistent challenges in gaining meaningful engagement with key opinion leaders (KOLs) and prescribers beyond initial product awareness
- Patient advocacy groups express frustration over delayed access to innovative treatments despite regulatory approval
- Market share for new products stagnates after initial launch, failing to meet internal projections despite significant investment in clinical trials and marketing
- Inefficient allocation of sales and medical liaison resources due to a lack of clear targets and understanding of local pathway dynamics
- Increased administrative burden for market access teams continually re-evaluating and adapting strategies for different regional health economies
- Significant unrealised revenue potential for pharmaceutical companies
- Reduced return on investment for R&D efforts in the UK market
- Delayed patient access to potentially life-changing therapies
- Suboptimal patient outcomes due to reliance on older, less effective treatments
- Perception of pharmaceutical company as slow to innovate or unresponsive to UK patient needs
- Erosion of trust with healthcare professionals and patient advocacy groups
The UK invests approximately 9% of its total healthcare expenditure on medicines, significantly lower than countries like Japan, which spends around 20% (ABPI, 2025)
Frequently asked questions
Why does this problem persist?
A lack of understanding of the complex factors influencing prescribing decisions in the UK, including local formularies, clinical guidelines, and peer networks, hinders effective product integration. This is compounded by insufficient engagement with the broader healthcare ecosystem beyond individual prescribers.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.